
|Videos|November 3, 2022
Available Induction Regimen Options for Patients with Transplant-Eligible NDMM
The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
3
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5

















































































